玄梗地黄汤治疗气阴两虚型IgA肾病的临床观察
|
摘要
目的：
本研究通过观察玄梗地黄汤对气阴两虚型IgA肾病(IgAnephropathy, IgAN)的中医症状积分及尿红细胞计数、24小时尿蛋白定量、血清免疫球蛋白(IgA、IgG、IgM)等实验室指标水平的影响,客观评价玄梗地黄汤对气阴两虚型IgA肾病的治疗作用,并探讨其作用机制。
方法：
将肾穿刺确诊为IgA肾病的患者按就诊顺序随机分为试验组(30例)和对照组(30例),试验组给予口服玄梗地黄汤每日1剂,对照组用单纯西医治疗(双嘧达莫),两组均治疗3个月。观察两组患者中医证候积分及尿红细胞计数、24小时尿蛋白定量、血清免疫球蛋白(IgG,IgM,IgA)等实验室指标水平的变化,并对比两组疗效。
结果：
1.两组疾病疗效比较：试验组总有效率86.6%,对照组总有效率63.3%,两组总有效率有显著性差异(u=2.24,P<0.05)。试验组的疾病疗效优于对照组。
2.两组证候疗效比较：试验组总有效率83.3%,对照组总有效率53.3%,两组总有效率有非常显著性差异(u=2.91,P<0.01)。试验组证候疗效明显优于对照组。
3.两组中医症状总积分比较：治疗后两组中医症状总积分组间比较,有非常显著性差异(P<0.01),试验组优于对照组。
4.两组单项症状积分比较：治疗后两组单项症状积分组间比较,在少气乏力,手足心热,易感冒症状改善方面,有非常显著性差异(P<0.01),在口干咽燥,浮肿的改善方面,有显著性差异(P<0.05),试验组明显优于对照组。
5.两组尿红细胞计数(/μL)比较：治疗后组间比较,有非常显著性差异(P<0.01),试验组改善血尿明显优于对照组。
6.两组24小时尿蛋白定量比较：治疗后组间比较,有显著性差异(P<0.05),试验组改善蛋白尿优于对照组。
7.两组血清免疫球蛋白比较：治疗后组间比较,仅血清IgA有显著性差异(P<0.05),试验组改善血清IgA优于对照组。
结论：
试验组能有效改善气阴两虚型IgA肾病患者的临床症状,尤其在少气乏力,手足心热,易感冒,口干咽燥,浮肿的症状改善方面,明显优于对照组,亦能有效减少血尿和蛋白尿,稳定肾功能,提高患者的生存质量,表明玄梗地黄汤是治疗气阴两虚型IgA肾病的有效方剂,为临床治疗气阴两虚型IgA肾病提供了新的、安全的治疗方法。
Objective:
To examine the effects of Xuangengdihuang Decoction on IgA nephropathy (IgA nephropathy, IgAN) of Qi and Yin Deficiency type,to calendar the syndrome integral and urinary red blood cell count,24-hour urinary protein, serum immunoglobulin (IgA, IgG, IgM),to evaluate the treatment of Xuangengdihuang Decoction on IgA nephropathy of Qi and Yin Deficiency type, and to explore the mechanisms.
Methods:
The patients diagnosed of IgAN were randomly divided into experimental group (30 cases) and control group (30 cases), experimental group were given daily Xuangengdihuang Decoction, The control group were treated with Western medicine alone (dipyridamole), two groups were treated for 3 months. TCM syndrome score and urinary red blood cell count,24-hour urinary protein, serum immunoglobulin (IgG, IgM, IgA), renal function (Ccr, Scr, BUN) levels and other changes in laboratory parameters were observed and compared in two groups.
Results:
1 Comparative efficacy of diseases:in experimental group, the total efficiency was 86.6%,in the control group, the total efficiency was 63.3%.Total effective rate was significantly different (u=2.24,P<0.05). The experimental group was better than the control group in the effect of disease.
2 Comparison of syndromes:the rate of experimental group was 83.3%,in the control group the rate was 53.3%, total effective rate was significantly different (u=2.91,P<0.01). The experimental group was better than the control group in syndromes.
3 Comparison of total score of clinical symptoms:After treatment, the total score of clinical symptoms between the two groups there was a significant difference (P<0.01), experimental group was better than the control group.
4 Comparison of individual symptom scores:After treatment, the individual symptom scores between the two groups in shortness of breath, lassitude, feverish sensations in the chest,palms and soles, vulnerable to cold, there was a significant difference(P<0.01),the scores in dryness in the mouth and throat,edema,there was a significant difference (P<0.05),experimental group was better than the control group.
5 Urinary red blood cell count (/μL) comparison:between the two groups after treatment, there was a significant difference (P<0.01), experimental group was better than the control group in the reducement of urinary red blood cell count.
624-hour urine protein comparison:between the two groups after treatment, there was a significant difference (P<0.05), the experimental group reduced 24-hour urinary protein better than the control group.
7 Serum immunoglobulin comparison:between the two groups after treatment, only a significant difference in IgA (P<0.05), experimental group reduced IgA better than the control group.
Conclution:
Experimental group can effectively improve the clinical symptoms of patients with type Qi and Yin Deficiency, especially in shortness of breath, lassitude, feverish sensations in the chest,palms and soles, vulnerable to cold, dryness in the mouth and throat, edema, and it is significantly better than the control group. Experimental group is also effective in reducing urine and proteinuria, stable renal function and improve quality of life of patients, indicating that Xuangengdihuang Decoction is an effective prescription for clinical treatment of IgA nephropathy of Qi and Yin Deficiency type and it may become a new, safe treatment.
本研究通过观察玄梗地黄汤对气阴两虚型IgA肾病(IgAnephropathy, IgAN)的中医症状积分及尿红细胞计数、24小时尿蛋白定量、血清免疫球蛋白(IgA、IgG、IgM)等实验室指标水平的影响,客观评价玄梗地黄汤对气阴两虚型IgA肾病的治疗作用,并探讨其作用机制。
方法：
将肾穿刺确诊为IgA肾病的患者按就诊顺序随机分为试验组(30例)和对照组(30例),试验组给予口服玄梗地黄汤每日1剂,对照组用单纯西医治疗(双嘧达莫),两组均治疗3个月。观察两组患者中医证候积分及尿红细胞计数、24小时尿蛋白定量、血清免疫球蛋白(IgG,IgM,IgA)等实验室指标水平的变化,并对比两组疗效。
结果：
1.两组疾病疗效比较：试验组总有效率86.6%,对照组总有效率63.3%,两组总有效率有显著性差异(u=2.24,P<0.05)。试验组的疾病疗效优于对照组。
2.两组证候疗效比较：试验组总有效率83.3%,对照组总有效率53.3%,两组总有效率有非常显著性差异(u=2.91,P<0.01)。试验组证候疗效明显优于对照组。
3.两组中医症状总积分比较：治疗后两组中医症状总积分组间比较,有非常显著性差异(P<0.01),试验组优于对照组。
4.两组单项症状积分比较：治疗后两组单项症状积分组间比较,在少气乏力,手足心热,易感冒症状改善方面,有非常显著性差异(P<0.01),在口干咽燥,浮肿的改善方面,有显著性差异(P<0.05),试验组明显优于对照组。
5.两组尿红细胞计数(/μL)比较：治疗后组间比较,有非常显著性差异(P<0.01),试验组改善血尿明显优于对照组。
6.两组24小时尿蛋白定量比较：治疗后组间比较,有显著性差异(P<0.05),试验组改善蛋白尿优于对照组。
7.两组血清免疫球蛋白比较：治疗后组间比较,仅血清IgA有显著性差异(P<0.05),试验组改善血清IgA优于对照组。
结论：
试验组能有效改善气阴两虚型IgA肾病患者的临床症状,尤其在少气乏力,手足心热,易感冒,口干咽燥,浮肿的症状改善方面,明显优于对照组,亦能有效减少血尿和蛋白尿,稳定肾功能,提高患者的生存质量,表明玄梗地黄汤是治疗气阴两虚型IgA肾病的有效方剂,为临床治疗气阴两虚型IgA肾病提供了新的、安全的治疗方法。
Objective:
To examine the effects of Xuangengdihuang Decoction on IgA nephropathy (IgA nephropathy, IgAN) of Qi and Yin Deficiency type,to calendar the syndrome integral and urinary red blood cell count,24-hour urinary protein, serum immunoglobulin (IgA, IgG, IgM),to evaluate the treatment of Xuangengdihuang Decoction on IgA nephropathy of Qi and Yin Deficiency type, and to explore the mechanisms.
Methods:
The patients diagnosed of IgAN were randomly divided into experimental group (30 cases) and control group (30 cases), experimental group were given daily Xuangengdihuang Decoction, The control group were treated with Western medicine alone (dipyridamole), two groups were treated for 3 months. TCM syndrome score and urinary red blood cell count,24-hour urinary protein, serum immunoglobulin (IgG, IgM, IgA), renal function (Ccr, Scr, BUN) levels and other changes in laboratory parameters were observed and compared in two groups.
Results:
1 Comparative efficacy of diseases:in experimental group, the total efficiency was 86.6%,in the control group, the total efficiency was 63.3%.Total effective rate was significantly different (u=2.24,P<0.05). The experimental group was better than the control group in the effect of disease.
2 Comparison of syndromes:the rate of experimental group was 83.3%,in the control group the rate was 53.3%, total effective rate was significantly different (u=2.91,P<0.01). The experimental group was better than the control group in syndromes.
3 Comparison of total score of clinical symptoms:After treatment, the total score of clinical symptoms between the two groups there was a significant difference (P<0.01), experimental group was better than the control group.
4 Comparison of individual symptom scores:After treatment, the individual symptom scores between the two groups in shortness of breath, lassitude, feverish sensations in the chest,palms and soles, vulnerable to cold, there was a significant difference(P<0.01),the scores in dryness in the mouth and throat,edema,there was a significant difference (P<0.05),experimental group was better than the control group.
5 Urinary red blood cell count (/μL) comparison:between the two groups after treatment, there was a significant difference (P<0.01), experimental group was better than the control group in the reducement of urinary red blood cell count.
624-hour urine protein comparison:between the two groups after treatment, there was a significant difference (P<0.05), the experimental group reduced 24-hour urinary protein better than the control group.
7 Serum immunoglobulin comparison:between the two groups after treatment, only a significant difference in IgA (P<0.05), experimental group reduced IgA better than the control group.
Conclution:
Experimental group can effectively improve the clinical symptoms of patients with type Qi and Yin Deficiency, especially in shortness of breath, lassitude, feverish sensations in the chest,palms and soles, vulnerable to cold, dryness in the mouth and throat, edema, and it is significantly better than the control group. Experimental group is also effective in reducing urine and proteinuria, stable renal function and improve quality of life of patients, indicating that Xuangengdihuang Decoction is an effective prescription for clinical treatment of IgA nephropathy of Qi and Yin Deficiency type and it may become a new, safe treatment.
引文
[1]王海燕.肾脏病学[M],北京：人民卫生出版社,2001,第2版：708.
[2]董德长.实用肾脏学[M],上海：上海科学技术出版社,1999,第1版：524.
[3]邹万忠.肾脏病理与临床[M],长沙：湖南科学技术出版社,1993,59.
[4]郑筱英.中药新药临床研究指导原则(试行)[M],北京：中国医药科技出版社,2002,157-162.
[5]孙建实.IgA肾病中医病因病机新探[J].中医药学报,2006,34(2)：1-2.
[6]刘玉宁,邓跃毅,王立红.陈以平教授治疗IgA肾病的临证经验[J].中国中西医结合肾病杂志,2003,4(6)：314-315.
[7]姚瑶,石君华.邵朝弟从五脏论治血尿的经验[J].湖北中医杂志,2010,32(3)：32-33.
[8]吴竞,杨爱国.清热利湿凉血和络法治疗IgA肾病40例分析[J].中医药学刊,2003,21(7)：1166-1167.
[9]杨爱国,安晓英,阮诗玮,等.辨证治疗单纯血尿性IgA肾病87例[J].江苏中医药,2003,24(5)：24-25.
[10]范立明,董金莉,林启展.林启展教授治疗IgA肾病经验介绍[J].新中医,2008,40(6)：8.
[11]程红彬.喉肾相关理论及其在肾炎治疗中的意义[J].实用中医药杂志,2009,25(4)：256-257.
[12]Matousovie K,Konecny K,Mestecky J,et al. IgA nephropathy. Significance of immunoglobulin A glycosylation in pathogenesis and clinical presentation[J]. Cas Let Cesk,2002, 141 (23):729-734.
[13]陈香美,陈仆.麦考酚酸酯治疗IgA肾病的随访对照观察[J].中华医学杂志,2002,82(12)：796-801.
[14]王海燕,王梅.慢性肾脏病及透析的临床实践指南[M].北京：人民卫生出版社.2005,175.
[15]金克峰,杨秀芹.短疗程糖皮质激素治疗IgA肾病临床观察[J].江西医学院学报,2009,49(6)：99-100.
[16]Suzuki T, Yamamoto T, Ohura M,et al. Clinioopathologic findings relevant to disappearance or relapse of proteinuria following corticosteroid treatment in IgA nephropathy patients with proteinuria of 0.5 to 2.0 g/d. Clin Exp Nephrol,2004,8(3):243-249
[17]Xie Y, NishiS,、Veno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int,2003,63:1861-1867.
[18]王军,王震,李更生,等.地黄苷A对“阴虚”及免疫功能低下的小鼠的药理作用[J].中国药学杂志,2002,37(1)：20-22.
[19]马健.生地黄对阴虚模型小鼠腹腔巨噬细胞对Ⅰa抗原表达的影响[J].中药药理与临床,1998,14(2)：22.
[20]是俊凤.黄芪注射液治疗慢性肾小球肾炎的观察[J].上海第二医科大学学报,2002,22(3)：246.
[21]李素教,严静霞,杨林,等.黄芪注射液对IgA肾病患者肾小管功能的影响[J].中国中西医结合杂志,2006,26(6)：504-506.
[22]阐建全,王雅茜,陈宗道,等.山药活性多糖抗突变作用的体外实验研究[J].营养学报,2001,23(1)：76-78.
[23]苗明三.怀山药多糖对小鼠免疫功能的增强作用[J].中药药理与临床,1997,13(3)：25-26.
[24]唐微,朱明磊,宋明华.山药多糖抗衰老作用的实验研究[J].黄冈职业技术学院学报,2002,4(3)：23-25.
[25]臧莲碧,郑怡健.山茱萸对小鼠抗氧化酶活力的影响[J].中国中医药科技,1994,1(6)：34-35.
[26]李洁,赵武述,丛笑,等.山茱萸的免疫药理活性[J].中日友好医院学报,1996,10(1)：43-45.
[27]金琦,曹静,王淑华.大剂量茯苓的药理作用及临床应用概况[J].浙江中医杂志,2003,38(9)：410-411.
[28]梅全喜,毕焕新.现代中药药理手册[M],北京：中国中医药出版社,1998,第1版：530.
[29]潘莉,成秀梅,常风云,等.益气活血通络法治疗以血尿为主的IgA肾病32例[J].中医杂志,2008,49(8)：718.
[1]孙建实.IgA肾病中医病因病机新探[J].中医药学报,2006,34(2)：1-2.
[2]曾莉,汤水福.洪钦国教授治疗IgA肾病经验简介[J].新中医,2010,42(5)：110.
[3]须冰.三焦理论与IgA肾病[J].中国中西医结合肾病杂志,2009,10(7)：656-658.
[4]欧娇英,蔡浙毅,刘琨.滋阴益肾方治疗IgA肾病的临床观察[J].辽宁中医杂志,2010,37(2)：296-297.
[5]丁英钧,潘莉,王月华,等.中药自拟方肾络通治疗以蛋白尿为主的IgA肾病临床研究[J].中国全科医学,2010,13(3A)：781-782.
[6]刘琨,蔡浙毅,沈冰,等.来氟米特联合中药治疗慢性进展性IgA肾病的临床研究[J].现代中西医结合杂志,2010,19(9)：1050.
[7]达展云,郭根凯,钱捷,等.补肾活血汤治疗IgA肾病[J].江苏医药,2010,36(4)：384-386.
[8]魏晓娜,檀金川,杨凤文,等.祛风渗湿方治疗IgA肾病患者40例[J].中医杂志,2010,51(6)：535.
[9]宋艳丽,夏滨祥,丁爱国,等.知柏地黄汤加味配合西药治疗IgA肾病50例的临床观察[J].黑龙江医药科学,2010,33(3)：67.
[10]冯高飞,王铁良.辨证分型治疗IgA肾病42例疗效观察[J].黑龙江中医药,2009,(1)：30-32.
[11]于小勇,程小红.IgA肾病中医辨证分型治疗新探[J].中国中西医结合肾病杂志,2009,10(11)：995-996.
[12]刘烨,沈惠风.辨证治疗IgA肾病血尿32例临床观察[J].河南中医,2005,25(1)：53.
[13]白玉华,黄芳.丁樱教授治疗IgA肾病的经验[J].中医研究,2009,22(3)：57-58.
[14]邹川,卢富华,黄春林.黄春林辨证结合辨病治疗IgA肾病的经验[J]. 江苏中医药,2009,41(4)：14-15.
[15]钟逸斐,陈以平,邓跃毅.肾安方治疗脾肾阳虚型IgA肾病临床现察[J].上海中医药杂志,2008,42(6)：40.
[16]侯卫国,高建东,关新,等.黄芪桂枝五物汤治疗脾肾阳虚型IgA肾病的临床研究[J].上海中医药大学学报,2008,22(3)：38-41.
[17]余仁欢,聂莉芳,徐建龙,等.益气滋肾颗粒干预IgA肾病蛋白尿的临床疗效评价[J].中国中西医结合肾病杂志,2010,11(8)：721.
[18]刘晓渭,陈威,许国双,等.灯盏花素联合福辛普利治疗IgA肾病的疗效观察[J].第四军医大学学报,2007,28(19)：1805.
[19]汤水福,洪钦国,罗月中,等.中西医结合治疗IgA肾病54例临床观察[J].中国中西医结合肾病杂志,2003,4(9)：517-519.
[20]覃国良.中西医结合治疗IgA肾病15例观察[J].实用中医药杂志,2010,26(1)：18-19.
[21]潘向荣.益气补肾活血法加小剂量强的松治疗IgA肾病[J].湖北中医杂志,2010,32(2)：56.
[22]周忠海,张俊凯,王卫松,等.中西医结合治疗IgA肾病临床观察[J].中国中医急症,2010,19(2)：229-230.
[23]张永秀,彭涛,郭玲,等.金水宝联合缬沙坦治疗IgA肾病疗效观察[J].实用医药杂志,2010,27(5)：413-414.
[2]董德长.实用肾脏学[M],上海：上海科学技术出版社,1999,第1版：524.
[3]邹万忠.肾脏病理与临床[M],长沙：湖南科学技术出版社,1993,59.
[4]郑筱英.中药新药临床研究指导原则(试行)[M],北京：中国医药科技出版社,2002,157-162.
[5]孙建实.IgA肾病中医病因病机新探[J].中医药学报,2006,34(2)：1-2.
[6]刘玉宁,邓跃毅,王立红.陈以平教授治疗IgA肾病的临证经验[J].中国中西医结合肾病杂志,2003,4(6)：314-315.
[7]姚瑶,石君华.邵朝弟从五脏论治血尿的经验[J].湖北中医杂志,2010,32(3)：32-33.
[8]吴竞,杨爱国.清热利湿凉血和络法治疗IgA肾病40例分析[J].中医药学刊,2003,21(7)：1166-1167.
[9]杨爱国,安晓英,阮诗玮,等.辨证治疗单纯血尿性IgA肾病87例[J].江苏中医药,2003,24(5)：24-25.
[10]范立明,董金莉,林启展.林启展教授治疗IgA肾病经验介绍[J].新中医,2008,40(6)：8.
[11]程红彬.喉肾相关理论及其在肾炎治疗中的意义[J].实用中医药杂志,2009,25(4)：256-257.
[12]Matousovie K,Konecny K,Mestecky J,et al. IgA nephropathy. Significance of immunoglobulin A glycosylation in pathogenesis and clinical presentation[J]. Cas Let Cesk,2002, 141 (23):729-734.
[13]陈香美,陈仆.麦考酚酸酯治疗IgA肾病的随访对照观察[J].中华医学杂志,2002,82(12)：796-801.
[14]王海燕,王梅.慢性肾脏病及透析的临床实践指南[M].北京：人民卫生出版社.2005,175.
[15]金克峰,杨秀芹.短疗程糖皮质激素治疗IgA肾病临床观察[J].江西医学院学报,2009,49(6)：99-100.
[16]Suzuki T, Yamamoto T, Ohura M,et al. Clinioopathologic findings relevant to disappearance or relapse of proteinuria following corticosteroid treatment in IgA nephropathy patients with proteinuria of 0.5 to 2.0 g/d. Clin Exp Nephrol,2004,8(3):243-249
[17]Xie Y, NishiS,、Veno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int,2003,63:1861-1867.
[18]王军,王震,李更生,等.地黄苷A对“阴虚”及免疫功能低下的小鼠的药理作用[J].中国药学杂志,2002,37(1)：20-22.
[19]马健.生地黄对阴虚模型小鼠腹腔巨噬细胞对Ⅰa抗原表达的影响[J].中药药理与临床,1998,14(2)：22.
[20]是俊凤.黄芪注射液治疗慢性肾小球肾炎的观察[J].上海第二医科大学学报,2002,22(3)：246.
[21]李素教,严静霞,杨林,等.黄芪注射液对IgA肾病患者肾小管功能的影响[J].中国中西医结合杂志,2006,26(6)：504-506.
[22]阐建全,王雅茜,陈宗道,等.山药活性多糖抗突变作用的体外实验研究[J].营养学报,2001,23(1)：76-78.
[23]苗明三.怀山药多糖对小鼠免疫功能的增强作用[J].中药药理与临床,1997,13(3)：25-26.
[24]唐微,朱明磊,宋明华.山药多糖抗衰老作用的实验研究[J].黄冈职业技术学院学报,2002,4(3)：23-25.
[25]臧莲碧,郑怡健.山茱萸对小鼠抗氧化酶活力的影响[J].中国中医药科技,1994,1(6)：34-35.
[26]李洁,赵武述,丛笑,等.山茱萸的免疫药理活性[J].中日友好医院学报,1996,10(1)：43-45.
[27]金琦,曹静,王淑华.大剂量茯苓的药理作用及临床应用概况[J].浙江中医杂志,2003,38(9)：410-411.
[28]梅全喜,毕焕新.现代中药药理手册[M],北京：中国中医药出版社,1998,第1版：530.
[29]潘莉,成秀梅,常风云,等.益气活血通络法治疗以血尿为主的IgA肾病32例[J].中医杂志,2008,49(8)：718.
[1]孙建实.IgA肾病中医病因病机新探[J].中医药学报,2006,34(2)：1-2.
[2]曾莉,汤水福.洪钦国教授治疗IgA肾病经验简介[J].新中医,2010,42(5)：110.
[3]须冰.三焦理论与IgA肾病[J].中国中西医结合肾病杂志,2009,10(7)：656-658.
[4]欧娇英,蔡浙毅,刘琨.滋阴益肾方治疗IgA肾病的临床观察[J].辽宁中医杂志,2010,37(2)：296-297.
[5]丁英钧,潘莉,王月华,等.中药自拟方肾络通治疗以蛋白尿为主的IgA肾病临床研究[J].中国全科医学,2010,13(3A)：781-782.
[6]刘琨,蔡浙毅,沈冰,等.来氟米特联合中药治疗慢性进展性IgA肾病的临床研究[J].现代中西医结合杂志,2010,19(9)：1050.
[7]达展云,郭根凯,钱捷,等.补肾活血汤治疗IgA肾病[J].江苏医药,2010,36(4)：384-386.
[8]魏晓娜,檀金川,杨凤文,等.祛风渗湿方治疗IgA肾病患者40例[J].中医杂志,2010,51(6)：535.
[9]宋艳丽,夏滨祥,丁爱国,等.知柏地黄汤加味配合西药治疗IgA肾病50例的临床观察[J].黑龙江医药科学,2010,33(3)：67.
[10]冯高飞,王铁良.辨证分型治疗IgA肾病42例疗效观察[J].黑龙江中医药,2009,(1)：30-32.
[11]于小勇,程小红.IgA肾病中医辨证分型治疗新探[J].中国中西医结合肾病杂志,2009,10(11)：995-996.
[12]刘烨,沈惠风.辨证治疗IgA肾病血尿32例临床观察[J].河南中医,2005,25(1)：53.
[13]白玉华,黄芳.丁樱教授治疗IgA肾病的经验[J].中医研究,2009,22(3)：57-58.
[14]邹川,卢富华,黄春林.黄春林辨证结合辨病治疗IgA肾病的经验[J]. 江苏中医药,2009,41(4)：14-15.
[15]钟逸斐,陈以平,邓跃毅.肾安方治疗脾肾阳虚型IgA肾病临床现察[J].上海中医药杂志,2008,42(6)：40.
[16]侯卫国,高建东,关新,等.黄芪桂枝五物汤治疗脾肾阳虚型IgA肾病的临床研究[J].上海中医药大学学报,2008,22(3)：38-41.
[17]余仁欢,聂莉芳,徐建龙,等.益气滋肾颗粒干预IgA肾病蛋白尿的临床疗效评价[J].中国中西医结合肾病杂志,2010,11(8)：721.
[18]刘晓渭,陈威,许国双,等.灯盏花素联合福辛普利治疗IgA肾病的疗效观察[J].第四军医大学学报,2007,28(19)：1805.
[19]汤水福,洪钦国,罗月中,等.中西医结合治疗IgA肾病54例临床观察[J].中国中西医结合肾病杂志,2003,4(9)：517-519.
[20]覃国良.中西医结合治疗IgA肾病15例观察[J].实用中医药杂志,2010,26(1)：18-19.
[21]潘向荣.益气补肾活血法加小剂量强的松治疗IgA肾病[J].湖北中医杂志,2010,32(2)：56.
[22]周忠海,张俊凯,王卫松,等.中西医结合治疗IgA肾病临床观察[J].中国中医急症,2010,19(2)：229-230.
[23]张永秀,彭涛,郭玲,等.金水宝联合缬沙坦治疗IgA肾病疗效观察[J].实用医药杂志,2010,27(5)：413-414.